PITX1 and hepatocellular carcinoma: In summary, this study showed that the ccf-mtDNA content in serum had a prognostic value for HBV-HCC patients receiving TACE combined with TCM treatment and may be used as a potential biomarker for the outcome prediction of HCC patients.